Literature DB >> 3978623

Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.

N E Sladek, G J Landkamer.   

Abstract

The sensitivity of cultured L1210 and P388 cells sensitive (L1210/0, P388/0) and resistant (L1210/OAP, P388/CLA) to oxazaphosphorines, to 4-hydroperoxycyclophosphamide, ASTA Z-7557, phosphoramide mustard, and acrolein was determined in the absence and presence of known (disulfiram, diethyldithiocarbamate, cyanamide) or suspected [ethylphenyl(2-formylethyl)phosphinate] inhibitors of aldehyde dehydrogenase activity. The L1210/OAP cell line is resistant specifically to the oxazaphosphorines; P388/CLA cells are partially cross-resistant to other cross-linking agents. All four inhibitors of aldehyde dehydrogenase activity potentiated the cytotoxic action of the oxazaphosphorines, 4-hydroperoxycyclophosphamide and ASTA Z-7557, against L1210/OAP and P388/CLA cells; in the presence of a sufficient amount of inhibitor, sensitivity was essentially fully restored in both cases. The inhibitors did not potentiate the cytotoxic action of the nonoxazaphosphorines, phosphoramide mustard and acrolein, against these cell lines. The cytotoxic action of the oxazaphosphorines and nonoxazaphosphorines against L1210/0 and P388/0 cells was not potentiated by any of the aldehyde dehydrogenase inhibitors. Inhibitors of xanthine oxidase or aldehyde oxidase activities did not potentiate the cytotoxic action of the oxazaphosphorines against L1210/OAP cells. These observations strongly suggest that (a) aldehyde dehydrogenase activity is an important determinant with regard to the sensitivity of a cell population to the oxazaphosphorines; (b) L1210/0 and P388/0 cells lack the relevant aldehyde dehydrogenase activity; (c) the phenotypic basis for the resistance to oxazaphosphorines by L1210/OAP cells is aldehyde dehydrogenase activity; and (d) the major reason that P388/CLA cells are resistant to oxazaphosphorines is aldehyde dehydrogenase activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978623

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Mechanisms of resistance to alkylating agents.

Authors:  G Damia; M D'Incalci
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study.

Authors:  J H Wu; C A Reynolds
Journal:  J Comput Aided Mol Des       Date:  2000-05       Impact factor: 3.686

4.  Cytotoxicity of diethyldithiocarbamate in human versus rodent cell lines.

Authors:  J D Cohen; H I Robins
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

Review 5.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

6.  UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells.

Authors:  Yang Wang; Cong-Hui Wang; Yu-Fei Zhang; Liang Zhu; Hui-Min Lei; Ya-Bin Tang
Journal:  Metabolomics       Date:  2019-03-25       Impact factor: 4.290

7.  The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.

Authors:  B A Teicher; T S Herman; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 8.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 9.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 10.  Aldehyde dehydrogenase 1A1 in stem cells and cancer.

Authors:  Hiroyuki Tomita; Kaori Tanaka; Takuji Tanaka; Akira Hara
Journal:  Oncotarget       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.